Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science
Cet article passe en revue les études concernant l'effet des anti-inflammatoires non stéroïdiens sur la carcinogenèse de l'œsophage, de l'estomac, du pancréas, du côlon-rectum et du foie
Growing evidence from epidemiologic and preclinical studies suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers, including esophageal, gastric, pancreatic, colorectal cancer, and hepatocellular carcinoma. However, there is also evidence indicating the absence of this benefit. The exact mechanism of NSAIDs’ action on GI tumors is not known. Although some studies have suggested inhibition of carcinogenesis by NSAIDs through suppression effect on inflammation-associated COX-2 expression, other studies have suggested cyclooxygenase-2 (COX-2)–independent mechanisms. Herein, we summarize the current state of-the-science regarding NSAID benefit for patients with GI cancers.
http://www.sciencedirect.com/science/article/pii/S0304383513006447